Lilly's Diabetes Pill Clears Major Trial, Analyst Points To Global Potential
1. LLY's orforglipron shows superior A1C reduction in Phase 3 trial. 2. BofA forecasts orforglipron sales could reach $10 billion by 2030. 3. Orforglipron's small molecule design enables easier production and scalability. 4. Positive trial results support LLY's focus on international oral drug markets. 5. LLY stock jumped 16.3% following the favorable trial results.